Impax's Flomax ANDA Triggers Patent Suit
Impax Laboratories Inc.'s bid to enter the billion-dollar U.S. market for prostate drug Flomax has prompted Astellas Pharma Inc. and Boehringer Ingleheim Pharmaceuticals Inc. to file a suit accusing Impax of...To view the full article, register now.
Already a subscriber? Click here to view full article